AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Abcellera Biologics Inc (NASDAQ:ABCL)
2.4447 USD
+0.075 3.152%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.37 |
|---|---|
| Change | +0.075 3.152% |
| 52 W H/L (in USD) | 6.055/2.335 |
| EBITDA (in USD) | -222.243M |
| PE Ratio | -- |
| Volume | 2456833 |
| Diluted Eps TTM | -0.61 |
| Total Assets (in USD) | 1488.094M |
|---|---|
| Total Liabilities (in USD) | 335.776M |
| Revenue TTM (in USD) | 32.962M |
| Cash (in USD) | 133.32M |
| Market Cap (in USD) | 871.330 M |
| Revenue Per Share TTM | 0.112 |
| Gross Profit TTM (in USD) | 311.109M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Abcellera Biologics Inc
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees: 586
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Carl L.G. Hansen Ph.D. | CEO, Pres & Chairperson | 1975 |
| 2. | Mr. Andrew Booth M.B.A. | Chief Financial Officer | 1974 |
| 3. | Dr. Veronique Lecault Ph.D. | COO & Director | 1985 |
| 4. | Mr. Tryn T. Stimart Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Corp. Sec. | 1970 |
| 5. | Dr. Ester Falconer Ph.D. | Chief Technology Officer | 1975 |
| 6. | Mr. Bo Barnhart Ph.D. | Scientific Director | NA |
| 7. | Ms. Tiffany Chiu B.Sc., Ph.D. | VP of Communications | NA |
| 8. | Mr. Murray McCutcheon Ph.D. | VP of Corp. Devel. | NA |
| 9. | Alexandra Weirich M.Sc. | Mang. of Marketing & Communications | NA |
| 10. | Caitlin Webster CIPD, M.Sc. | Sr. Mang. of People & Culture | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 239.099M | -2.211M | 157.833M | -2.211M | 0.309M |
| Minority Interest | - | - | - | - | - |
| Net Income | 158.519M | -2.211M | 118.918M | -2.42M | 0.309M |
| Selling General Administrative | 55.485M | 2.749M | 11.91M | 2.749M | 2.151M |
| Gross Profit | 418.988M | 11.612M | 206.012M | 11.612M | 8.831M |
| Reconciled Depreciation | 33.102M | 17.25M | 5.271M | 1.847M | 0.918M |
| Ebit | 216.511M | -2.002M | 156.031M | -4.117M | 0.883M |
| Ebitda | 276.246M | -0.155M | 169.915M | -0.341M | 1.801M |
| Depreciation And Amortization | 59.735M | 1.847M | 13.884M | 3.776M | 0.918M |
| Operating Income | 216.511M | -4.117M | 156.031M | -4.117M | -0.753M |
| Other Operating Expenses | 258.359M | 13.954M | 68.804M | 13.954M | 7.99M |
| Interest Expense | 4.045M | 0.209M | 6.511M | 0.209M | 0.212M |
| Tax Provision | 80.58M | 65.685M | 38.915M | - | 0M |
| Interest Income | 16.079M | 3.33M | 0.293M | 0.155M | 0.042M |
| Net Interest Income | 12.034M | -1.895M | -6.218M | -0.054M | -0.17M |
| Income Tax Expense | 80.58M | 65.685M | 38.915M | 0.209M | 1.274M |
| Total Revenue | 485.424M | 11.612M | 233.155M | 11.612M | 8.831M |
| Total Operating Expenses | 191.923M | 13.954M | 41.661M | 13.954M | 7.99M |
| Cost Of Revenue | 66.436M | 45.516M | 27.143M | - | 0M |
| Total Other Income Expense Net | 22.588M | 1.906M | 1.802M | 1.906M | -0.362M |
| Net Income From Continuing Ops | 158.519M | 153.464M | 118.918M | -2.211M | 0.309M |
| Net Income Applicable To Common Shares | 158.519M | 153.464M | 118.918M | -2.211M | 0.292M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1488.094M | 1540.907M | 1318.569M | 1005.536M | 23.488M |
| Intangible Assets | 120.425M | 131.502M | 148.392M | 115.153M | - |
| Other Current Assets | 20.911M | 75.413M | 21.247M | 5.97M | 0.71M |
| Total Liab | 335.776M | 307.63M | 292.836M | 175.028M | 13.236M |
| Total Stockholder Equity | 1152.318M | 1233.277M | 1025.733M | 830.508M | 10.252M |
| Other Current Liab | 61.276M | 57.975M | 77.471M | 76.706M | 0.129M |
| Common Stock | 753.199M | 734.365M | 722.43M | 710.387M | 5.122M |
| Capital Stock | 753.199M | 734.365M | 722.43M | 710.387M | 12.668M |
| Retained Earnings | 279.787M | 426.185M | 267.666M | 114.202M | -4.716M |
| Good Will | 47.806M | 47.806M | 47.806M | 31.5M | - |
| Other Assets | - | 84.431M | 30.642M | 8.388M | 2.368M |
| Cash | 133.32M | 386.535M | 476.142M | 594.116M | 7.553M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 119.013M | 118.32M | 120.676M | 103.49M | 7.895M |
| Current Deferred Revenue | 26.07M | 21.612M | 7.536M | 6.589M | 3.236M |
| Net Debt | -55.94M | -304.277M | -439.729M | -588.013M | -0.662M |
| Short Term Debt | 6.158M | 5.583M | 3.652M | 0.19M | 2.886M |
| Short Long Term Debt | - | - | - | 0.19M | 2.467M |
| Short Long Term Debt Total | 77.38M | 82.258M | 36.413M | 6.103M | 6.891M |
| Other Stockholder Equity | 121.052M | 74.118M | 35.357M | 5.919M | 2.3M |
| Property Plant Equipment | - | 217.255M | 111.616M | 17.923M | 8.48M |
| Total Current Assets | 871.985M | 1025.491M | 929.8M | 813.325M | 12.64M |
| Long Term Investments | 65.938M | 72.522M | 50.313M | 19.247M | - |
| Short Term Investments | 627.265M | 499.95M | 246.835M | 594.116M | - |
| Net Receivables | 64.382M | 38.593M | 160.576M | 213.239M | 4.378M |
| Long Term Debt | - | - | - | 2.198M | 1.363M |
| Inventory | 1.107M | 1.532M | 1.672M | 1.408M | 0.163M |
| Accounts Payable | 25.509M | 33.15M | 32.017M | 20.005M | 1.643M |
| Accumulated Other Comprehensive Income | -1.72M | -1.391M | 0.28M | - | -3.157M |
| Non Currrent Assets Other | 94.244M | 46.331M | 23.234M | 8.388M | 2.368M |
| Non Current Assets Total | 616.109M | 515.416M | 388.769M | 192.211M | 10.848M |
| Capital Lease Obligations | 77.38M | 82.258M | 36.413M | 3.715M | 3.061M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -352.625M | -277.425M | -19.247M | -5.78M | -5.307M |
| Total Cashflows From Investing Activities | -352.625M | -332.247M | -119.78M | -5.78M | -5.307M |
| Total Cash From Financing Activities | -1.628M | -3.886M | 683.653M | 0.195M | 12.186M |
| Net Income | 158.519M | 153.464M | 118.918M | -2.211M | 0.309M |
| Change In Cash | -86.492M | -92.974M | 586.563M | -2.891M | 10.444M |
| Begin Period Cash Flow | 501.142M | 594.116M | 7.553M | 10.444M | -0M |
| End Period Cash Flow | 414.65M | 501.142M | 594.116M | 7.553M | 10.444M |
| Total Cash From Operating Activities | 277.36M | 244.584M | 22.69M | 2.694M | 3.565M |
| Depreciation | 33.102M | 17.25M | 5.271M | 1.847M | 0.918M |
| Other Cashflows From Investing Activities | -2.935M | 3.63M | 1.783M | -1.783M | -1.783M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 40.919M | -134.348M | - | -0.898M |
| Sale Purchase Of Stock | - | -0.011M | 0M | -0.011M | - |
| Other Cashflows From Financing Activities | -1.305M | -2.063M | 180.755M | 0.605M | 10.473M |
| Capital Expenditures | 72.66M | 58.452M | 14.673M | 3.997M | 5.307M |
| Change In Working Capital | 29.825M | 41.672M | -116.701M | 1.973M | 1.911M |
| Other Non Cash Items | 8.547M | 3.57M | 4.707M | 0.194M | -0.188M |
| Free Cash Flow | 204.7M | 186.132M | 8.017M | -1.303M | -1.742M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Federated Hermes Imp Opps Eq X USD Acc | 8 months ago | 225489 |
| 2. | Allianz Global Artfcl Intlgc W EUR | 7 months ago | 6103119 |
| 3. | Baillie Gifford Positive Change B Acc | 7 months ago | 4793590 |
| 4. | Baillie Gifford Positive Change | 7 months ago | 4751912 |
| 5. | UBS (Lux) Digital Health Equity SB USD | 7 months ago | 4500000 |
| 6. | SMDS Global AI Equity Mother | 1 year ago | 4490520 |
| 7. | Baillie Gifford WW Pstv Chg B USD Acc | 7 months ago | 2823111 |
| 8. | iShares Biotechnology ETF | 6 months ago | 1415401 |
| 9. | Lazard Digital Health | 8 months ago | 1035697 |
| 10. | ACATIS Datini Valueflex Fonds A | 7 months ago | 1000000 |
| 11. | Mediolanum BB Global Impact L | 1 year ago | 555383 |
| 12. | Desjardins Sustainable Positive Change F | 6 months ago | 469124 |
| 13. | Vanguard Baillie GiffordGlbPstvImpStkInv | 8 months ago | 454435 |
| 14. | Edinburgh Worldwide Ord | 9 months ago | 417365 |
| 15. | Keystone Positive Change Investment Ord | 8 months ago | 403923 |
| 16. | BlackRock Advantage Small Cap Core Instl | 7 months ago | 363294 |
| 17. | SEB Artificial Intelligence D (USD) | 7 months ago | 340267 |
| 18. | iShares Genomics Immnlgy & Hlthcr ETF | 6 months ago | 321017 |
| 19. | iShares Healthcare Innov ETF USD Acc | 6 months ago | 303689 |
| 20. | Baillie Gifford International Alp CIT C | 1 year ago | 245489 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Baker Bros Advisors LP | 8 months ago | 27525640 |
| 2. | Baillie Gifford & Co Limited. | 8 months ago | 12894703 |
| 3. | ING Investment Management LLC | 8 months ago | 10624185 |
| 4. | Prosight Management, LP | 8 months ago | 9079539 |
| 5. | UBS Asset Mgmt Americas Inc | 8 months ago | 4590103 |
| 6. | Orbimed Advisors, LLC | 8 months ago | 4180768 |
| 7. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 8 months ago | 4105095 |
| 8. | BlackRock Inc | 11 months ago | 3803477 |
| 9. | Renaissance Technologies Corp | 8 months ago | 2946703 |
| 10. | Two Sigma Investments LLC | 8 months ago | 2533635 |
| 11. | TANG CAPITAL MANAGEMENT LLC | 8 months ago | 2300000 |
| 12. | Federated Hermes Inc | 8 months ago | 2282696 |
| 13. | Two Sigma Advisers, LLC | 8 months ago | 2177600 |
| 14. | Guardian Capital Advisors LP | 8 months ago | 1786414 |
| 15. | Citadel Advisors Llc | 8 months ago | 1499640 |
| 16. | Novo A/S | 8 months ago | 1126915 |
| 17. | Lazard Asset Management LLC | 8 months ago | 1096575 |
| 18. | NORGES BANK | 11 months ago | 922214 |
| 19. | Opaleye Management Inc | 8 months ago | 800000 |
| 20. | Millennium Management LLC | 8 months ago | 753887 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...